| Literature DB >> 36082155 |
Longjun Guo1, Jianing Xi1, Jiaqi Teng1, Juan Wang1, Yukun Chen1.
Abstract
Since the early 1980s when MRI imaging technology was put into clinical use, the number of MRI clinical tests has steadily increased by more than 10% every year. At the same time, exogenous MRI contrast agents have also been developed with the development of MRI technology. However, there are still challenges in the preparation of contrast agents for magnetic resonance imaging, such as how to prepare high-efficiency contrast agents with high stability and low biological toxicity. In order to study the contrast agent with simple preparation method, low cost, and good imaging effect, a magnetic resonance contrast agent was prepared by magnetic nanoparticles. By acting on magnetic resonance imaging detection method, and using polymer ligands to synthesize magnetic nanoparticles, experiments and tests of P(MA-alt-VAc) polymer ligand-modified magnetic nanoparticles were carried out. The experimental results showed that when nanoparticles containing different iron ion concentrations were incubated with DC 2.4 normal cells for 48 hours, the cell viability was still higher than 80% at concentrations up to 200 μm. It shows that the nanoparticle has high cell activity and good biological adaptability. The transverse relaxation (r 2) value of the nanoparticles in aqueous solution at 37°C and 1.5 T magnetic field is 231.1 m-1 s-1, which is much higher than that of PTMP-PMAA (r 2 = 35.1 mM-1 s-1), which is also more than five times the relaxation of SHU-555C (r 2 = 44 mM-1 s-1). It shows that the nanoparticles prepared in this paper have good effect and can be used as a contrast agent in human brain for magnetic resonance imaging.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36082155 PMCID: PMC9448598 DOI: 10.1155/2022/6790665
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Imaging modalities employed in molecular imaging and system of detection.
| Molecular imaging mode | Detection method |
|---|---|
| X-ray computed tomography | X-ray |
| Single photon emission computed tomography | Low energy gamma rays |
| Positron emission tomography | High energy gamma rays |
| Magnetic resonance imaging | Radio frequency waves |
| Optical imaging | Near infrared light |
| Ultrasound imaging | Ultrasound |
Figure 1Contrast agent nanoparticles crossing the brain in the presence of a magnet.
Figure 2Materials used for the functionalization of magnetic nanoparticles.
Figure 3Different strategies for the protection/stabilization of IONPs.
Organic macromolecules and their advantages of functionalized iron oxide NPs.
| Types of polymers | Polymers | Characteristics |
|---|---|---|
| Natural polymers | Dextran | Enables optimum polar interactions with iron oxide surfaces, improves the blood circulation time, stability, and biocompatibility |
| Chitosan | Nontoxic, alkaline, hydrophilic, widely used as nonviral gene delivery system, biocompatible, and hydrophilic | |
| Starch | Improves the biocompatibility, good for MRI and drug target delivery | |
| Gelatin | Used as a gelling agent, hydrophilic emulsifier, biocompatible | |
|
| ||
| Synthetic polymers | Polyethylene glycol (PEG) | Enhances the hydrophilicity and water solubility, improves the biocompatibility, blood circulation times |
| Polyvinyl alcohol (PVA) | Prevents agglomeration, giving rise to monodispersibility | |
| Polymethyl methacrylate (PMMA) | Generally used as thermosensitive drug delivery and cell separation | |
| Polyacrylic acid (PAA) | Improves stability and biocompatibility as well as bioconjugation | |
Apparatuses.
| Equipment name | Model |
|---|---|
| Thermogravimetric analyzer | TGA-7 |
| X-ray diffractometer | Bruker D8 Advance |
| Vibrating sample magnetometer | Lakeshore 7400 |
| Vacuum drying oven | DZF-6020 |
| Rotary evaporator | SHZ-D(III) |
| Digital constant temperature magnetic stirrer | RCT-basic |
| NMR analyzer | minispec mq 60 1.41T |
Figure 4Synthesis of polymer ligand P(MA-alt-VAc).
Figure 5Synthesis of polymer ligand modified Fe3O4 nanoparticles.
Figure 6Results of the DLS test.
Figure 7Results of the nanoparticles dispersed in various concentrations of sodium chloride water.
Figure 8Viability of the DC 2.4 cells and MCF-7 tumor cells incubated after 24 h and 48 h.
Figure 9Brain T2-weighted MRI image before and after injection.
Figure 10Weighted images of nanoparticles at different concentration.